In October 2007, the FDA announced which the labeling for all PDE5 inhibitors, including tadalafil, needs a far more notable warning on the likely chance of sudden hearing reduction as the results of post-advertising stories of temporary deafness associated with utilization of PDE5 inhibitors.[19]